PPARγ inhibitors enhance the efficacy of statin therapy for steroid-induced osteonecrosis of the femoral head by directly inhibiting apoptosis and indirectly modulating lipoprotein subfractions.

<h4>Background</h4>Steroid-induced osteonecrosis of the femoral head (SONFH) is a serious bone disease commonly seen in patients on long-term glucocorticoid therapy. Although statins have shown some efficacy in improving lipid metabolism, their efficacy in the treatment of SONFH remains...

Full description

Saved in:
Bibliographic Details
Main Authors: Kai-Yun Chen, Xu-Huan Li, Dan Chen, Shi-da Qian, Run-Hong Mei, Qian Li, Xue-Feng Yu, Xi-Jing He
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0325190
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849473360716627968
author Kai-Yun Chen
Xu-Huan Li
Dan Chen
Shi-da Qian
Run-Hong Mei
Qian Li
Xue-Feng Yu
Xi-Jing He
author_facet Kai-Yun Chen
Xu-Huan Li
Dan Chen
Shi-da Qian
Run-Hong Mei
Qian Li
Xue-Feng Yu
Xi-Jing He
author_sort Kai-Yun Chen
collection DOAJ
description <h4>Background</h4>Steroid-induced osteonecrosis of the femoral head (SONFH) is a serious bone disease commonly seen in patients on long-term glucocorticoid therapy. Although statins have shown some efficacy in improving lipid metabolism, their efficacy in the treatment of SONFH remains limited. PPARγ inhibitors may enhance the efficacy of statins through several mechanisms. This study aims to investigate how PPARγ inhibitors may enhance the effects of statins in the treatment of SONFH by directly inhibiting apoptosis and indirectly modulating lipoprotein subfractions.<h4>Methods</h4>We first treated osteoblasts in vitro with high concentrations of hormones to simulate the SONFH environment. We then treated the cells with either the PPARγ inhibitor GW9662, the statin lovastatin, or a combination of both. We assessed cell proliferation and apoptosis using CCK-8, flow cytometry and Western blotting. We then established a SONFH rabbit model using high doses of methylprednisolone and lipopolysaccharide. The rabbits were randomly divided into four groups: control group, lovastatin group, GW9662 group and combination therapy group. We observed hip joint MRI before treatment, after 4 weeks of treatment, and 4 weeks after stopping treatment. We performed hematoxylin-eosin staining of the femoral head and analysed serum lipoprotein subfractions using VAP technology. In addition, we used quantitative polymerase chain reaction (qPCR) to analyse the expression of genes related to lipid metabolism at week 3.<h4>Results</h4>In vitro experiments showed that both GW9662 and lovastatin effectively inhibited hormone-induced apoptosis. In the animal studies, imaging and pathological results showed that the progression of SONFH was slower in the combination therapy group than in the other groups. VAP analysis showed that the lovastatin group had disturbed lipoprotein subfractions at the fourth week after stopping treatment, while the combination therapy group had more stable lipoprotein subfractions.<h4>Conclusion</h4>PPARγ inhibitors significantly enhance the efficacy of statins in the treatment of SONFH by directly inhibiting apoptosis and indirectly modulating lipoprotein subfractions. These findings provide new insights into the clinical management of SONFH and suggest that combination therapy may be an effective strategy.
format Article
id doaj-art-0f4f5c15c3cd4cf2b2f307edcd1e457e
institution Kabale University
issn 1932-6203
language English
publishDate 2025-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-0f4f5c15c3cd4cf2b2f307edcd1e457e2025-08-20T03:24:10ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01206e032519010.1371/journal.pone.0325190PPARγ inhibitors enhance the efficacy of statin therapy for steroid-induced osteonecrosis of the femoral head by directly inhibiting apoptosis and indirectly modulating lipoprotein subfractions.Kai-Yun ChenXu-Huan LiDan ChenShi-da QianRun-Hong MeiQian LiXue-Feng YuXi-Jing He<h4>Background</h4>Steroid-induced osteonecrosis of the femoral head (SONFH) is a serious bone disease commonly seen in patients on long-term glucocorticoid therapy. Although statins have shown some efficacy in improving lipid metabolism, their efficacy in the treatment of SONFH remains limited. PPARγ inhibitors may enhance the efficacy of statins through several mechanisms. This study aims to investigate how PPARγ inhibitors may enhance the effects of statins in the treatment of SONFH by directly inhibiting apoptosis and indirectly modulating lipoprotein subfractions.<h4>Methods</h4>We first treated osteoblasts in vitro with high concentrations of hormones to simulate the SONFH environment. We then treated the cells with either the PPARγ inhibitor GW9662, the statin lovastatin, or a combination of both. We assessed cell proliferation and apoptosis using CCK-8, flow cytometry and Western blotting. We then established a SONFH rabbit model using high doses of methylprednisolone and lipopolysaccharide. The rabbits were randomly divided into four groups: control group, lovastatin group, GW9662 group and combination therapy group. We observed hip joint MRI before treatment, after 4 weeks of treatment, and 4 weeks after stopping treatment. We performed hematoxylin-eosin staining of the femoral head and analysed serum lipoprotein subfractions using VAP technology. In addition, we used quantitative polymerase chain reaction (qPCR) to analyse the expression of genes related to lipid metabolism at week 3.<h4>Results</h4>In vitro experiments showed that both GW9662 and lovastatin effectively inhibited hormone-induced apoptosis. In the animal studies, imaging and pathological results showed that the progression of SONFH was slower in the combination therapy group than in the other groups. VAP analysis showed that the lovastatin group had disturbed lipoprotein subfractions at the fourth week after stopping treatment, while the combination therapy group had more stable lipoprotein subfractions.<h4>Conclusion</h4>PPARγ inhibitors significantly enhance the efficacy of statins in the treatment of SONFH by directly inhibiting apoptosis and indirectly modulating lipoprotein subfractions. These findings provide new insights into the clinical management of SONFH and suggest that combination therapy may be an effective strategy.https://doi.org/10.1371/journal.pone.0325190
spellingShingle Kai-Yun Chen
Xu-Huan Li
Dan Chen
Shi-da Qian
Run-Hong Mei
Qian Li
Xue-Feng Yu
Xi-Jing He
PPARγ inhibitors enhance the efficacy of statin therapy for steroid-induced osteonecrosis of the femoral head by directly inhibiting apoptosis and indirectly modulating lipoprotein subfractions.
PLoS ONE
title PPARγ inhibitors enhance the efficacy of statin therapy for steroid-induced osteonecrosis of the femoral head by directly inhibiting apoptosis and indirectly modulating lipoprotein subfractions.
title_full PPARγ inhibitors enhance the efficacy of statin therapy for steroid-induced osteonecrosis of the femoral head by directly inhibiting apoptosis and indirectly modulating lipoprotein subfractions.
title_fullStr PPARγ inhibitors enhance the efficacy of statin therapy for steroid-induced osteonecrosis of the femoral head by directly inhibiting apoptosis and indirectly modulating lipoprotein subfractions.
title_full_unstemmed PPARγ inhibitors enhance the efficacy of statin therapy for steroid-induced osteonecrosis of the femoral head by directly inhibiting apoptosis and indirectly modulating lipoprotein subfractions.
title_short PPARγ inhibitors enhance the efficacy of statin therapy for steroid-induced osteonecrosis of the femoral head by directly inhibiting apoptosis and indirectly modulating lipoprotein subfractions.
title_sort pparγ inhibitors enhance the efficacy of statin therapy for steroid induced osteonecrosis of the femoral head by directly inhibiting apoptosis and indirectly modulating lipoprotein subfractions
url https://doi.org/10.1371/journal.pone.0325190
work_keys_str_mv AT kaiyunchen pparginhibitorsenhancetheefficacyofstatintherapyforsteroidinducedosteonecrosisofthefemoralheadbydirectlyinhibitingapoptosisandindirectlymodulatinglipoproteinsubfractions
AT xuhuanli pparginhibitorsenhancetheefficacyofstatintherapyforsteroidinducedosteonecrosisofthefemoralheadbydirectlyinhibitingapoptosisandindirectlymodulatinglipoproteinsubfractions
AT danchen pparginhibitorsenhancetheefficacyofstatintherapyforsteroidinducedosteonecrosisofthefemoralheadbydirectlyinhibitingapoptosisandindirectlymodulatinglipoproteinsubfractions
AT shidaqian pparginhibitorsenhancetheefficacyofstatintherapyforsteroidinducedosteonecrosisofthefemoralheadbydirectlyinhibitingapoptosisandindirectlymodulatinglipoproteinsubfractions
AT runhongmei pparginhibitorsenhancetheefficacyofstatintherapyforsteroidinducedosteonecrosisofthefemoralheadbydirectlyinhibitingapoptosisandindirectlymodulatinglipoproteinsubfractions
AT qianli pparginhibitorsenhancetheefficacyofstatintherapyforsteroidinducedosteonecrosisofthefemoralheadbydirectlyinhibitingapoptosisandindirectlymodulatinglipoproteinsubfractions
AT xuefengyu pparginhibitorsenhancetheefficacyofstatintherapyforsteroidinducedosteonecrosisofthefemoralheadbydirectlyinhibitingapoptosisandindirectlymodulatinglipoproteinsubfractions
AT xijinghe pparginhibitorsenhancetheefficacyofstatintherapyforsteroidinducedosteonecrosisofthefemoralheadbydirectlyinhibitingapoptosisandindirectlymodulatinglipoproteinsubfractions